 Paclitaxel has been combined with platinum compounds, primarily cisplatin in several studies. A phase II study that combined paclitaxel 175 mgm2 as a 3-hour infusion with cisplatin 75 mgm2 reported a 67 response rate. There were seven complete responses and nine partial responses with an 18 month median overall survival. An additional phase II study evaluated the efficacy of combining paclitaxel and carboplatin in both primary advanced and recurrent non-papillary and papillary tumors following radiation. The response rate was 78 in patients with primary advanced non-papillary tumors with a median disease-free survival of 23 months, with the median overall survival not being reached at the time of publication. Furthermore, patients with recurrent endometrial cancer had a response rate of 56, with a median overall survival of 15 months. 